Background: Several lines of evidence suggest that most of the early-onset forms of familial Alzheimer's disease (FAD) 
Introduction
A network of independent studies has led to the suggestion that the presenilins (PS) likely con- (4, 5, 6, 8) . Interestingly, we recently showed that mutations on PS1 could also trigger decreased secretion of the physiological secreted product APPa (9) . Although it is not yet demonstrated, it can be postulated that PS likely interfere with or control the routing of ,APP, as these two proteins often colocalize in the central nervous system (10) (11) (12) and are able to physically interact (13, 14) .
We previously established that the proteasome contributes to the a-secretase pathway. Thus, two proteasome inhibitors, lactacystin and Z-IE (Ot-Bu)A-Leucinal, increased constitutive APPa secretion by human cells. Furthermore, the proteasome appears to exert a dual control over protein kinase C (PKC)-regulated APPa secretion by human kidney (HEK)293 cells, as short-term treatment of these cells with proteasome inhibitors led to enhanced recovery of APPa whereas prolonged exposure of the cells triggered decreased APPa recovery (1 5,16) . We established that PKC effectors modified neither the proteasome activity nor its basal phosphorylation state (17) in vitro and in vivo. This indicates that the proteasome does not correspond to a-secretase itself, and it suggests the likely occurrence of another intermediate involved in f3APP processing that should behave as a substrate of this multicatalytic complex.
We present here evidence that wild-type and familial Alzheimer's disease (FAD)-linked PS1 behave as substrates of the proteasome in stably transfected HEK293 cells. Furthermore, we demonstrate that proteasome inhibitors modulate the production of AP3 secretion by these cells, and particularly, that they exacerbate the phenotypic overproduction of A,B42 by cells overexpressing the mutated forms of PS1. Combined with our previous studies, these data suggest that the proteasome could control the intracellular levels of PSI, upstream to PSI and ,BAPP interaction, thereby influencing the production of physiological and pathogenic catabolites of f3APP maturation.
Materials and Methods
Molecular Cloning of PSI and Mutagenesis PSI was cloned as previously described (18 labeled for 6 hr as described earlier (20 16 .5% Tris-tricine electrophoresis, and radioautographed as described earlier (9) . Densitometric analysis was performed by phosphorImager (Fuji).
Antibodies FCA3340 and FCA3542 specifically interact with Af340 and A,B42, respectively (21) . aPSILoop recognizes the hydrophilic loop of PS1 located between its predicted sixth and seventh transmembrane domain (19 Figure 2A clearly shows that both inhibitors strongly protect wtPS 1 immunoreactivity, in a time-dependent manner. These agents concomittantly potentiate the recovery of both HMW-PSI and LMW-PS1 (Fig. 2B) , although the protection appears particularly strong for LMW-PS 1. It should be noted that the two proteasome inhibitors also unmask a trail of PS i-related immunoreactivity that increases with time ( Fig. 2A) . These agents do not significantly alter the recovery of CTF-PS 1 generated by these cells. Figure 3A indicates that the treatment of wtPS 1-expressing transfectants with a 25 ,uM concentration of Z-IE(Ot-Bu)A-Leucinal strongly enhances both HMW-PS1 and LMW-PS1 immunoreactivity. Lactacystin also elicits a dose-dependent protection of PSI immunoreactivity (Fig. 3A) , with a maximal protection at 5 ,uM, the extent of which resembles that elicited by 25 ,uM of Z-IE(Ot-Bu)A-Leucinal (Fig. 3A) . Here again, both HMW-PS 1 and LMW-PS 1 appear concomittantly protected from the degradation process (Fig. 3B) . Control experiments indicate that the addition of Z-IE(Ot-Bu)A-Leucinal during the extraction procedure did not affect PSI immunoreactivity, therefore ruling out the possible artefactual contribution of the proteasome during this step of the procedure (Fig. 3A, lane c) .
In agreement with the current knowledge on proteasome intracellular targets, we have established that immunoprecipitated wtPS1 can be labeled with anti-ubiquitin-specific antibodies (Fig. 4) (Fig. 4) (Fig. SB) .
We examined the effect of the two proteasome inhibitors on the PS immunoreactivity in cells overexpressing mutated or AE9-PS 1 like immunoreactivity in all transfected cells (Fig. 6A) . The extent of protection of HMW-PS1 and LMW-PS 1 immunoreactivity obtained with 5 ,uM and 25 ,uM of lactacystin and Z-IE(OtBu)A-Leucinal, respectively, appears very similar. Both agents led to higher protection of LMW-PS 1 immunoreactivity (Fig. 6B) . Independent transfectant clones expressing identical mutated PS responded similarly to the proteasome inhibitors. Table 1 documents the increased immunoreactivity of both HMW-and LMW-PS 1, the latter showing particularly strong immunoreactivity.
We assessed whether the proteasome inhibitors could affect pathogenic JAPP maturation and particularly whether they could modify the ratio of Af342 to total AP3 (A,B40 + Af42) secretion by transfected cells. Mock transfected HEK293 cells (naive cells) secrete low amounts of A,B40 and A342 (Fig. 7A, B (12, 25) . We also observe an additional product of about 25 kDa (CTF-PS1) that likely corresponds to the C-terminal product of PSI maturation. In line of such hypothesis, it should be noted that the overexpression of AE9-PS 1, a nonmaturated PSI construction (19), does not lead to the detection of such CTF-PS1 immunoreactivity (Fig. 1) . The fact that the molecular weight of CTF-PS1 appears to be slightly higher than those previously reported could reflect a high phosphorylation state of this product in our conditions (26, 27) . Two specific inhibitors of the proteasomal multicatalytic complex, lactacystin and Z-IE(OtBu)A-Leucinal, elicit time-and dose-dependent protection of wtPS 1 immunoreactivity. These agents also trigger identical protection of FADlinked M146V-PS1, H163R-PS1, and E280A-PS 1. This is not accompanied by a concommitant decrease in CTF-PS1 immunoreactivity, thereby indicating that the inhibitors more likely prevent a proteasomal contribution to PS1 degradation but not maturation. Accordingly, the same protection was observed with the cells expressing the maturation-resistant AE9-PS 1 construction.
Interestingly, both LMW-PS 1 and HMW-PS 1 immunoreactivity is affected by proteasome inhibitors, although the extent of inhibition appears to be clearly higher for LMW-PS 1. The nature of LMW-PS1 and HMW-PS1 is not yet clear. However, they do not correspond to distinct glycosylation states (not shown), which is in agreement with the fact that the main subcellular immunohistochemical localization of PS includes cell compartments involved early in biosynthetic pathways, such as endoplasmic reticulum and early Golgi (10) (11) (12) . The current knowledge of proteasome specificity indicates that this catalytic complex triggers the degradation of intracellular polyubiquitinated proteins (28) . In this context, it is interesting to note that PS1 can undergo polyubiquitination in HEK293 E28OA-PS1-i5 (Fig. 4) , as was shown for PS2 (29) . Several lines of evidence now suggest that although mainly cytosolic, the proteasome could also be detected in other cell compartments (30, 31) lead to increased production of both A,340 and A,B42 but clearly favor the production of the latter species as reflected by the increased Af342 to total A,B ratio. Proteasome inhibitors protect mutated PSI from degradation, thereby exacerbating A,342 production as reflected by an increase of this ratio. Altogether, our study suggests that the proteasome participates in the degradation of wt and mutated PSI and directly influences A,B production. It should be noted that direct involvement of the proteasome in Af3 degradation is unlikely, as we previously demonstrated that the purified enzyme was unable to cleave synthetic A,B in vitro (15) .
We previously established that proteasome inhibitors could increase the constitutive secretion of APPa (16) , the physiological product of ,BAPP maturation (38) . These data, together with the present study strongly suggest that the proteasome influences both a-and f3/y-secretase pathways, probably through the degradation of PS 1. These catabolic events likely occur upstream to the contribution of PSI to the maturation and/or routing of fAPP. Furthermore, the selective increased secretion of A,B42 observed with cells expressing FAD-linked PS1 strongly supports a dysfunction in the ,BAPP routing brought about by these mutations. A recent study seems to indicate that the proteasome could also contribute to the degradation of wild-type presenilin 2 (29) .
Whether the proteasome could serve as therapeutic target remains to be established. It is interesting to note, however, that several natural endogenous activators of the proteasome have been described (for reviews, see refs. 39,40) . In the case of early-onset forms of Alzheimer's disease linked to mutations on PS1, it is thus possible to envision that selective enhancers of the proteasome activity could diminish A,42 formation through increased degradation of mutated PSI and therefore slow down or arrest the neu-rodegenerative process that is likely related to overexpression of such A,B42 species.
